This site is intended for healthcare professionals
CDK4/6 inhibitors in breast cancer

CME accredited module

Read time: 60 mins
Last updated:19th Jul 2021
Published:19th Jul 2021

Are you aware of the latest trends and studies on early breast cancer recurrence and risk stratification? Take our interactive CME eLearning module to explore the evidence that supports the risk of recurrence in early breast cancer, treatment options available, methods being used for assessing the risk of recurrence and the clinical trial data on the three approved CDK4/6 inhibitors.

Early breast cancer and risk stratification

This module is to Oncologists, Breast Surgeons, and all healthcare professional involved in dealing with early breast cancer. Improve your ability to support your patient with early breast cancer with our EACCME® accredited CME module on ‘Early breast cancer and risk stratification.’

Enrol

Section outline Content outline Time (60 mins total)
Section 1 Early breast cancer and risk of recurrence 15 mins
Section 2 Managing high-risk early breast cancer – treatment, monitoring and preventing recurrence 15 mins
Section 3 Strategies for early breast cancer risk stratification 15 mins
Section 4 Clinical trials for CDK4/6 inhibition in high-risk early breast cancer 15 mins

Course overview

How confident are you with understanding early breast cancer, its treatment and risk stratification?  Take this interactive CME course to explore aspects of early breast cancer with our clinical experts offering their advice throughout the course.

System Requirements

Faculty

Dr Laura Spring, MD

Dr Laura Spring, MD, is a Medical Oncologist and clinical researcher at the Massachusetts General Hospital Cancer Center and Harvard Medical School. Dr Spring is particularly interested in targeted therapies in the neoadjuvant setting and has conducted multiple breast cancer research trials for localised metastatic breast cancer.

Professor Nadia Harbeck, MD, PhD

Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany. Professor Harbeck is a member of the expert panel issuing the yearly updated evidence based AGO Guidelines for breast cancer therapy in Germany. She is a panel member of several international breast cancer consensus conferences and is the recipient of many awards, including the 2020 ESMO Lifetime Achievement Award.

Professor Stephen Johnston, MD, PhD

Stephen Johnston is Professor of Breast Cancer Medicine, Consultant Medical Oncologist and Head of The Breast Unit at the Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London. He was appointed Head of Medical Oncology at The Royal Marsden in 2019, having previously been the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre for Cancer at The Royal Marsden from 2006-12.He is actively involved in facilitating the interface between basic and applied research and has been Chief Investigator of several phase II / III trials of novel endocrine-based therapeutic approaches in both advanced and early-stage disease, including one of the large global adjuvant CDK4/6 inhibitor studies in early breast cancer.

Further information

Evaluation questions will be asked at the end of each module. You must achieve a score of 70% or above to pass the course and receive your CME certificate.

At the end of the course, you will also be asked to complete a short survey, giving you the chance to provide feedback on your experience of the module.

On completion of this course, participants will understand:

  • The risk of recurrence in early breast cancer and the risk factors associated with it
  • The emerging treatment options for treating patients with breast cancer and the prevention strategies being used
  • How to identify the level of risk of recurrence in breast cancer and the tools and algorithms used to assess this risk
  • The aims, results, and differences of the three CDK4/6 inhibitors currently approved to treat early breast cancer patients

Early breast cancer and risk stratification

This module is to Oncologists, Breast Surgeons, and all healthcare professional involved in dealing with early breast cancer. Improve your ability to support your patient with early breast cancer with our EACCME® accredited CME module on ‘Early breast cancer and risk stratification.’

Enrol